Annovis Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$28.9MTTM through 30 Jun 2026
Free Cash Flow -$43.3MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-130.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Net Debt-$14.2Mnet cash position
Cash & Equivalents$18.7M
Quality Metrics
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPS-$1.75TTMFY2025: $-1.40
Dividend
No dividend
Capital Allocation
R&D Spend$43.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Buntanetap Clinical Development | $0 | View detailsSymptomatic data readout for Phase 3 Alzheimer's trial is anticipated approximately 6 months after the last patient is dosed (expected summer 2026), with disease-modifying data readout expected 18 months after. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.